T2 Biosystems Inc (TTOO)

[lecorb]

BlackRock Inc. boosted its stake in T2 Biosystems by 34.6% in the third quarter. BlackRock Inc. now owns 2,203,844 shares of the medical equipment provider’s stock worth $2,998,000 after buying an additional 566,115 shares in the last quarter. Geode Capital Management LLC increased its stake in T2 Biosystems by 100.5% in the first quarter. Geode Capital Management LLC now owns 759,200 shares of the medical equipment provider’s stock valued at $493,000 after purchasing an additional 380,459 shares in the last quarter. Hussman Strategic Advisors Inc. bought a new stake in T2 Biosystems in the third quarter valued at approximately $350,000. Bridgeway Capital Management Inc. boosted its holdings in shares of T2 Biosystems by 161.6% in the second quarter. Bridgeway Capital Management Inc. now owns 404,700 shares of the medical equipment provider’s stock valued at $514,000 after buying an additional 250,000 shares during the period. Finally, California Public Employees Retirement System acquired a new position in shares of T2 Biosystems in the third quarter valued at approximately $299,000. 10.06% of the stock is owned by institutional investors.
A number of other research firms have also commented on TTOO. ValuEngine raised shares of T2 Biosystems from a “hold” rating to a “buy” rating in a research report on Wednesday, September 2nd. Zacks Investment Research lowered shares of T2 Biosystems from a “buy” rating to a “hold” rating in a research report on Tuesday, October 13th. Canaccord Genuity lowered their price target on shares of T2 Biosystems from $4.00 to $3.50 and set a “buy” rating on the stock in a research report on Thursday. Alliance Global Partners raised their price target on shares of T2 Biosystems from $1.65 to $2.60 and gave the stock a “buy” rating in a research report on Thursday. Finally, BTIG Research assumed coverage on shares of T2 Biosystems in a research report on Wednesday, October 7th. They set a “buy” rating and a $2.50 price target on the stock. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $2.62.
https://www.americanbankingnews.com/2020/11/09/t2-biosystems-inc-nasdaqttoo-forecasted-to-post-fy2020-earnings-of-0-38-per-share.html